NASDAQ:GLUE

Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis

Monte Rosa Therapeutics logo
$8.90 -0.17 (-1.87%)
As of 02:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)

Advanced

Key Stats

Today's Range
$8.75
▼
$9.28
50-Day Range
$9.07
▼
$14.32
52-Week Range
$8.75
▼
$25.77
Volume
613,261 shs
Average Volume
1.36 million shs
Market Capitalization
$759.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.44
Consensus Rating
Moderate Buy

Company Overview

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments.

The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway. Monte Rosa has also studied MRT-2359, a GSPT1 degrader for certain cancers.

Founded in 2019, Monte Rosa is headquartered in Boston, Massachusetts, and has operations in Basel, Switzerland. The company is led by co-founder and Chief Executive Officer Markus Warmuth.

AI Generated. May Contain Errors.

Monte Rosa Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

GLUE MarketRank™: 
1.921188982815 of 5 stars

Monte Rosa Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 1319th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Monte Rosa Therapeutics has a consensus price target of $26.44, representing about 197.3% upside from its current price of $8.89.

  • Amount of Analyst Coverage

    Monte Rosa Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Monte Rosa Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monte Rosa Therapeutics are expected to decrease in the coming year, from ($0.94) to ($1.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monte Rosa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monte Rosa Therapeutics is -6.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monte Rosa Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    26.12% of the float of Monte Rosa Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15.68, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Monte Rosa Therapeutics has recently increased by 0.95%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Monte Rosa Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monte Rosa Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Monte Rosa Therapeutics has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Monte Rosa Therapeutics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monte Rosa Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137.00 in company stock.

  • Percentage Held by Insiders

    6.40% of the stock of Monte Rosa Therapeutics is held by insiders.

  • Percentage Held by Institutions

    79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Monte Rosa Therapeutics' insider trading history.
Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GLUE Stock News Headlines

Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis
Chase, Wells Fargo and Capital One all showed errors on Nov. 16
On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when trying to reach their money. The outage lasted hours. Cedar Gold Group points out that physical gold has no login, no server and needs no one's permission. Its free Wealth Protection Playbook shows how to keep part of your savings outside the banking system.tc pixel
HC Wainwright Has Bullish Forecast for GLUE FY2026 Earnings
See More Headlines

GLUE Stock Analysis - Frequently Asked Questions

Monte Rosa Therapeutics' stock was trading at $15.68 at the beginning of the year. Since then, GLUE shares have decreased by 43.3% and is now trading at $8.8940.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) announced its quarterly earnings data on Thursday, November, 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.24. The business had revenue of $54.37 million for the quarter, compared to analysts' expectations of $33.87 million. Monte Rosa Therapeutics had a negative trailing twelve-month return on equity of 30.14% and a negative net margin of 186.24%.

Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering (IPO) on Wednesday, June 23rd 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share.

Monte Rosa Therapeutics' top institutional shareholders include State Street Corp (4.36%), Goldman Sachs Group Inc. (1.02%), Nantahala Capital Management LLC (0.84%) and Empowered Funds LLC (0.45%). Insiders that own company stock include Versant Venture Capital Vi, L, Markus Warmuth, Sharon Townson, Jennifer Champoux, Filip Janku, Filip Janku, Philip Nickson, Matthew Bowen, Edmund Dunn, Chandra P Leo and Anthony M Manning.
View institutional ownership trends
.

Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include NVIDIA (NVDA), Atai Beckley (ATAI), Broadcom (AVGO), CorMedix (CRMD), Definium Therapeutics (DFTX), Denali Therapeutics (DNLI) and GH Research (GHRS).

Company Calendar

Last Earnings
11/05/2026
Today
11/19/2026
38th Annual Healthcare Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GLUE
CIK
1826457
Fax
N/A
Employees
173
Year Founded
2018

Price Target and Rating

High Price Target
$37.00
Low Price Target
$19.00
Potential Upside/Downside
+198.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.40)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.63 million
Net Margins
-186.24%
Pretax Margin
-184.77%
Return on Equity
-30.14%
Return on Assets
-20.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.32
Quick Ratio
10.32

Sales & Book Value

Annual Sales
$70.33 million
Price / Sales
10.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.81 per share
Price / Book
1.53

Miscellaneous

Outstanding Shares
85,450,000
Free Float
79,981,000
Market Cap
$757.51 million
Optionable
Optionable
Beta
1.40

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:GLUE) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners